We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Voluntary codes of conduct established by industry groups to control pharmaceutical companies’ marketing practices are ineffective and routinely abused by drugmakers, contends the watchdog group Public Citizen, which yesterday released a study documenting promotional abuses at an industry convention.
The Center for Drug Evaluation and Research (CDER) plans to conduct focus group studies on a number of topics in 2006, including direct-to-consumer (DTC) advertising and physician labeling.
The FDA's recent decision to convene focus groups to study potential changes to the agency's policy on direct-to-consumer (DTC) advertising is part of an FDA effort to stall reform while an interim commissioner heads the agency, according to industry experts.
The FDA’s recent decision to convene focus groups to study potential changes to the agency’s policy on direct-to-consumer (DTC) advertising is part of an FDA effort to stall reform while an interim commissioner heads the agency, according to industry experts.
A class-action lawsuit accusing AstraZeneca of waging a misleading promotional campaign to deceive patients into buying its heartburn drug Nexium has been dismissed in a Delaware federal court.
State governments are starting to place more pressure on pharmaceutical companies to provide greater disclosure of their sales practices in light of mounting concerns that promotional activities are inflating drug prices and misleading doctors, various state sources and attorneys say.
The UK’s health watchdog is ratcheting up enforcement of misleading drug promotions, announcing this week that it intends to review all promotional materials for newly licensed medicines before they are disseminated.
State governments are starting to place more pressure on pharmaceutical companies to provide greater disclosure of their sales practices in light of mounting concerns that promotional activities are inflating drug prices and misleading doctors, various state sources and attorneys say.
A class-action lawsuit accusing AstraZeneca of waging a misleading promotional campaign to deceive patients into buying its heartburn drug Nexium was dismissed this week in a Delaware federal court.
The UK’s health watchdog is ratcheting up enforcement of misleading drug promotions, announcing this week that it intends to review all promotional materials for newly licensed medicines before they are disseminated.